People: Pfizer Inc (PFE)

PFE on New York Consolidated

29.95USD
31 Oct 2014
Price Change (% chg)

$0.11 (+0.37%)
Prev Close
$29.84
Open
$30.01
Day's High
$30.20
Day's Low
$29.81
Volume
25,196,027
Avg. Vol
24,702,812
52-wk High
$32.96
52-wk Low
$27.51

Search Stocks

Summary

Name Age Since Current Position

Ian Read

60 2011 Chairman of the Board, Chief Executive Officer

Frank D'Amelio

56 2010 Chief Financial Officer, Executive Vice President - Business Operations

Albert Bourla

52 2014 Group President - Vaccines, Oncology and Consumer Healthcare Business

Mikael Dolsten

55 2010 President - Worldwide Research and Development

Geno Germano

53 2014 Group President - Global Innovative Pharma Business

John Young

49 2014 Group President - Global Established Pharma Business

Rady Johnson

52 2013 Executive Vice President, Chief Compliance and Risk Officer

Douglas Lankler

48 2014 Executive Vice President, General Counsel

Charles Hill

58 2010 Executive Vice President - Worldwide Human Resources

Freda Lewis-Hall

59 2010 Executive Vice President, Chief Medical Officer

Anthony Maddaluna

61 2013 Executive Vice President, President - Pfizer Global Supply

Laurie Olson

50 2012 Executive Vice President - Strategy, Portfolio and Commercial Operations

Sally Susman

52 2010 Executive Vice President - Corporate Affairs

George Lorch

73 2011 Lead Independent Director

Shantanu Narayen

50 2013 Director

James Smith

54 2014 Director

Dennis Ausiello

68 2006 Independent Director

W. Don Cornwell

66 1997 Independent Director

Frances Fergusson

69 2009 Independent Director

Helen Hobbs

61 2011 Independent Director

Constance Horner

72 2010 Independent Director

James Kilts

66 2007 Independent Director

Suzanne Nora Johnson

56 2007 Independent Director

Stephen Sanger

68 2009 Independent Director

Marc Tessier-Lavigne

54 2011 Independent Director

Ryan Crowe

IR Contact Officer

Biographies

Name Description

Ian Read

Mr. Ian C. Read is Chairman of the Board, Chief Executive Officer of Pfizer Inc. He was President and Chief Executive Officer from December 2010. Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Mr. Read began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well. Director of Kimberly-Clark Corporation. Mr. Read serves on the Boards of Pharmaceutical Research and Manufacturers of America (PhRMA) and the Partnership of New York City. Member of the President’s Export Council and U.S.-China Business Council.

Frank D'Amelio

Mr. Frank A. D'Amelio is Chief Financial Officer, Executive Vice President - Business Operations of Pfizer Inc., since December 2010. He was Senior Vice President and Chief Financial Officer from September 2007 until December 2010. Prior to joining Pfizer, he was Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent from November 2006 until August 2007. Director of Zoetis Inc. and of Humana, Inc. and Chair of the Humana Audit Committee. He is a Director of the Independent College Fund of New Jersey and the Gillen Brewer School.

Albert Bourla

Mr. Albert Bourla has been appointed as Group President - Vaccines, Oncology and Consumer Healthcare Business of Pfizer Inc., effective January 1, 2014. He was President and General Manager of Established Products Business Unit from December 2010 until December 2013. Area President Europe, Africa, Asia and Pacific of Pfizer Animal Health from 2009 until November 2010. Area President Europe, Africa and Middle East of Pfizer Animal Health from 2005 until 2009.

Mikael Dolsten

Dr. Mikael Dolsten, M.D., Ph.D., is President - Worldwide Research and Development of Pfizer Inc., since December 2010. He was Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008.

Geno Germano

Mr. Geno J. Germano is Group President - Global Innovative Pharma Business of Pfizer Inc., since January 2014. He was President and General Manager, Pfizer Specialty Care and Oncology from December 2010 until December 2013. President and General Manager, Specialty Care from October 2009 until December 2010. President, U.S. Pharmaceuticals and Women’s Health Care Unit, Wyeth Pharmaceuticals from 2008 through October 2009. President and General Manager, U.S. Pharmaceutical Business Unit, Wyeth Pharmaceuticals from 2007 through 2008. Member of the Board of Trustees for Albany College of Pharmacy and Health Sciences and Member of the Board of Directors of BIO - Biotechnology Industry Organization. Director of Zoetis Inc. from July 2012 until June 2013.

John Young

Mr. John D. Young is Group President - Global Established Pharma Business of Pfizer Inc., since June 1, 2012. He was President and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Unit’s Regional President for Europe and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until 2009.

Rady Johnson

Mr. Rady A. Johnson is Executive Vice President, Chief Compliance and Risk Officer of Pfizer Inc. He was Senior Vice President and Associate General Counsel from October 2006 until December 2013.

Douglas Lankler

Mr. Douglas M. Lankler is Executive Vice President, General Counsel of Pfizer Inc. He was Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Senior Vice President, Associate General Counsel and Chief Compliance Officer from October 2006 until August 2009.

Charles Hill

Mr. Charles H. Hill, III, is Executive Vice President - Worldwide Human Resources of Pfizer Inc., since December 2010. He served as Senior Vice President, Human Resources for Worldwide Biopharmaceuticals Businesses from 2008 through December 2010. Vice President, Human Resources, Worldwide Pharmaceutical Operations from 2004 through 2008. Director of Zoetis Inc. from July 2012 until June 2013.

Freda Lewis-Hall

Dr. Freda C. Lewis-Hall, M.D., is Executive Vice President, Chief Medical Officer of Pfizer Inc., since December 2010. She served as Senior Vice President, Chief Medical Officer from May 2009 until December 2010. Previously, she was Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals from June 2008 until May 2009. Dr. Lewis-Hall was Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008.

Anthony Maddaluna

Mr. Anthony J. Maddaluna is Executive Vice President, President - Pfizer Global Supply of Pfizer Inc., since January 2013. He was President, Pfizer Global Supply from 2011 until December 2012. Senior Vice President, Strategy & Supply Network Transformation from 2009 until December 2010. Vice President, Strategy & Supply Network Transformation from 2008 until 2009. Vice President and Team Leader, Europe from 1998 until 2008 including responsibility for global logistics and strategic planning from 2005 through 2008. Mr. Maddaluna represents Pfizer on the National Association of Manufacturers (NAM) and is a member of the NAM Executive Committee.

Laurie Olson

Ms. Laurie J. Olson serves as the Executive Vice President - Strategy, Portfolio and Commercial Operations of Pfizer Inc., since July 2012. She was Senior Vice President - Strategy and Portfolio Management from 2011 until July 2012. Senior Vice President - Portfolio Management and Analytics from 2008 until 2010. Since joining Pfizer in 1987 as an Analyst in the Company's marketing research organization, Ms. Olson has served in a variety of marketing leadership positions with increasing responsibility in both the Company’s U.S. and global commercial organizations.

Sally Susman

Ms. Sally Susman is Executive Vice President - Corporate Affairs of Pfizer Inc., since December 2010. She served as Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Senior Vice President and Chief Communications Officer from February 2008 until December 2009. Prior to joining Pfizer, Ms. Susman held senior level positions at The Estée Lauder Companies, including Executive Vice President from 2004 to January 2008. Director of WPP plc.

George Lorch

Mr. George A. Lorch is Lead Independent Director of Pfizer Inc. Mr. Lorch is Chairman Emeritus of Armstrong Holdings, Inc., a global manufacturer of flooring and ceiling materials, since 2000, having served as Chairman and Chief Executive Officer and in other executive capacities with Armstrong Holdings, Inc. and its predecessor, Armstrong World Industries, Inc., from 1993 to 2000. Director of Autoliv, Inc., Masonite International, Inc., and WPX Energy, Inc., and also a Director of HSBC Finance Corporation and HSBC North America Holding Company, wholly owned subsidiaries of HSBC LLC (Mr. Lorch announced his intention to retire in April 2014). Director of Williams Companies, Inc. from 2001 until 2011.

Shantanu Narayen

Mr. Shantanu Narayen is Director of Pfizer Inc., since September 27, 2013. Mr. Narayen is President and Chief Executive Officer and Director of Adobe Systems Incorporated, a producer of creative and digital marketing software. Prior to his appointment as CEO in December of 2007, Mr. Narayen held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development. Director of Dell Inc. from 2009 until October 2013 and Director of Metavante Technologies Inc. from 2007 until 2009. He serves as President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world. He is a member of the U.S. President’s Management Advisory Board, established in 2010 to provide advice on how to implement best business practices.

James Smith

Mr. James C. Smith is Director of the Company. Mr. Smith is the President and Chief Executive Officer (CEO) of Thomson Reuters and serves on its Board of Directors. Prior to his appointment as CEO in January 2012, he held various leadership positions at Thomson Reuters, including CEO and Chief Operating Officer (COO) of Thomson Reuters Professional Division. Prior to the acquisition of Reuters PLC by Thomson, he served as COO of Thomson and President and CEO of Thomson Learning’s Academic and Reference Group. Mr. Smith is a member of the International Business Council of the World Economic Forum and the Board of Directors of the Brazil-U.S. Business Council. He also serves on the International Advisory Boards of British American Business and the Atlantic Council.

Dennis Ausiello

Dr. Dennis A. Ausiello, M.D., is Independent Director of Pfizer Inc., since December 2006. He is Director, Center for Assessment Technology and Continuous Health (CATCH). Physician-in-Chief, Emeritus at Massachusetts General Hospital and Chief of Medicine at Massachusetts General Hospital from 1996 until April 2013. Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. President of the Association of American Physicians in 2006. Member of the Institute of Medicine of the National Academies of Science and a Fellow of the American Academy of Arts and Sciences. Director of Alnylam Pharmaceuticals, TARIS BioMedical, Inc. and several non-profit organizations. Member of scientific advisory boards of Bind Therapeutics and Blend Therapeutics.

W. Don Cornwell

Mr. W. Don Cornwell is Independent Director of Pfizer Inc., since February 1997. He has been Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporation from 1988 until his retirement in August 2009 and Vice Chairman until December 2009. Granite Broadcasting Corporation filed for voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code in December 2006 and emerged from its restructuring in June 2007. Director of American International Group, Inc. and Avon Products, Inc. Director of the Wallace Foundation from 2002 until 2012. Trustee of Big Brothers/Sisters of New York.

Frances Fergusson

Dr. Frances D. Fergusson, Ph.D., is Independent Director of Pfizer Inc., since September 25, 2009. Dr. Fergusson is President Emeritus of Vassar College since 2006 and President from 1986 to 2006. Served on the Mayo Clinic Board for 14 years, the last four years as its Chairman, and as President of the Board of Overseers of Harvard University from 2007 through 2008. Director of Wyeth from 2005 until 2009. Director of Mattel, Inc. She serves as a Trustee on the executive committees of the Getty Trust, The School of American Ballet and Second Stage Theatre and as a director of The John and Mable Ringling Museum of Art Foundation, Inc.

Helen Hobbs

Dr. Helen Hobbs, M.D., is Independent Director of Pfizer Inc., since December 12, 2011. She is Investigator of the Howard Hughes Medical Institute since 2002, a Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. In 2007, Dr. Hobbs was elected to the National Academy of Sciences and received the Distinguished Scientist Award from the American Heart Association. Dr. Hobbs was elected to the Institute of Medicine in 2004 and the American Academy of Arts and Sciences in 2006. She is a member of the American Society of Clinical Investigation and the Association of American Physicians. Director of the Dallas Heart Study. She received the International Society of Atherosclerosis Prize in 2012. In 2005 she became the first recipient of the Clinical Scientist Award from the American Heart Association and was awarded Germany’s Heinrich Wieland Prize.

Constance Horner

Ms. Constance J. Horner is Independent Director of Pfizer Inc., since 1993. She was Guest Scholar from 1993 until 2005 at The Brookings Institution, an organization devoted to nonpartisan research, education and publication in economics, government, foreign policy and the social sciences. Commissioner of the U.S. Commission on Civil Rights from 1993 to 1998. Served at the White House as Assistant to President George H. W. Bush and as Director of Presidential Personnel from 1991 to 1993. Deputy Secretary, U.S. Department of Health and Human Services, from 1989 to 1991. Director of the U.S. Office of Personnel Management from 1985 to 1989. Director of Ingersoll-Rand plc and Prudential Financial, Inc.; Fellow, National Academy of Public Administration; and Member of the Board of Trustees of the Prudential Foundation.

James Kilts

Mr. James M. Kilts is Independent Director of Pfizer Inc., since September 27, 2007. He is Founding Partner, Centerview Capital, a private equity firm, since 2006. Vice Chairman, The Procter & Gamble Company, from 2005 to 2006. Chairman and Chief Executive Officer, The Gillette Company, from 2001 to 2005 and President, The Gillette Company, from 2003 to 2005. President and Chief Executive Officer, Nabisco Group Holdings Corporation, from 1998 until its acquisition in 2000. Chairman of the Nielsen Company B.V. Supervisory Board and Non-Executive Director and Chairman (until December 31, 2013) of the Board of Nielsen Holdings N.V., Director of Meadwestvaco Corporation and MetLife, Inc., Trustee of Knox College and the University of Chicago, and a member of the Board of Overseers of Weill Cornell Medical College.

Suzanne Nora Johnson

Ms. Suzanne Nora Johnson is Independent Director of Pfizer Inc., since September 27, 2007. She is Retired Vice Chairman, Goldman Sachs Group, Inc., since 2007. During her 21-year tenure with Goldman Sachs, she served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care. Director of American International Group, Inc., Intuit Inc. and VISA Inc. Member of the Board of Governors of the American Red Cross, Vice Chair, Board of Trustees of The Brookings Institution, Co-Chairman of the Board of Trustees of the Carnegie Institution of Washington and member of the Board of Trustees of the University of Southern California.

Stephen Sanger

Mr. Stephen W. Sanger is Independent Director of Pfizer Inc., since February 1, 2009. He served as Chairman of General Mills, Inc., a packaged food producer and distributor, from 1995 until his retirement in 2008 and its Chief Executive Officer from 1995 to 2007. Former Chairman of the Grocery Manufacturers of America. Recipient of the Woodrow Wilson Award for Public Service in 2009. Chaired the Fiscal Policy Committee of the Business Roundtable and served as a director of Catalyst. Director of Wells Fargo & Company. Director of Target Corporation from 1996 until 2013. Our Director since 2009.

Marc Tessier-Lavigne

Dr. Marc Tessier-Lavigne, Ph.D., is Independent Director of Pfizer Inc., since December 12, 2011. He is President of The Rockefeller University since March 2011, Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University. Between 2003 and 2011, held positions of increasing responsibility at Genentech, a leading biopharmaceutical company, where he became Executive Vice President, Research, and Chief Scientific Officer. Susan B. Ford Professor in the School of Humanities and Sciences, and Professor of Biological Sciences and of Neurology and Neurological Sciences at Stanford University from 2001 to 2003, and a faculty member at the University of California, San Francisco from 1991 to 2001. In addition, Dr. Tessier-Lavigne was a Howard Hughes Medical Institute Investigator from 1994 to 2003. Director of Regeneron Pharmaceuticals, Inc., Agios Pharmaceuticals Inc. and Juno Therapeutics, Inc. Member of the National Academy of Sciences and its Institute of Medicine, and a Fellow of the Royal Society (U.K.), the Royal Society of Canada, the Academy of Medical Sciences (U.K.) and the American Association for the Advancement of Science. Director of the Rockefeller Archive Center and Federal Reserve Bank of New York and also serves on various scientific boards.

Ryan Crowe

Search Stocks